PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings • Drug profiles PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Clinical application • Treatment guidelines • Key buying criteria PART 05: Hypercholesterolemia: An overview • History of hypercholesterolemia • Hypercholesterolemia management market dynamics • Hypercholesterolemia prescription landscape • Management of hypercholesterolemia • Epidemiology • Unmet medical needs and role of PCSK9 and CETP inhibitors PART 06: Pipeline portfolio • Information on pipeline candidates PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Segmentation by type of disease • FH • Non-FH PART 09: Market segmentation by MOA • HMG-CoA reductase inhibitors • Fibric acid derivatives • Nicotinic acid • Bile acid sequestrants • Other PART 10: Market segmentation by drug class • Statins • Non-statins PART 11: Geographical segmentation • Global hypercholesterolemia drugs market by geographical segmentation 2015-2020 • Hypercholesterolemia drugs market in Americas • Hypercholesterolemia drugs market in EMEA • Hypercholesterolemia drugs market in APAC PART 12: Market drivers • Increasing risk of CVDs • Rising prevalence of chronic diseases • Promising pipeline of drugs • Change in ATP guidelines for management of hypercholesterolemia • Growing older population PART 13: Impact of drivers PART 14: Market challenges • Loss of patent exclusivity of branded therapies • Drawbacks associated with current therapies • High cost of therapy • Stringent regulatory guidelines • Lack of proper diagnosis PART 15: Impact of drivers and challenges PART 16: Market trends • Expected entry of cost-effective OTC versions • Increasing use of statins • Increased use of combination therapies • Consideration of lifestyle management in ATP guidelines PART 17: Vendor landscape • Competitive scenario • Market share analysis 2015 PART 18: Key vendor analysis • AbbVie • Aegerion Pharmaceuticals • AstraZeneca • Merck • Pfizer • Sanofi • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio   Exhibit 01: Product offerings Exhibit 02: Different class of lipoproteins Exhibit 03: Evaluation of lipoprotein levels based on ATP III classification Exhibit 04: Key buying criteria for hypercholesterolemia drugs Exhibit 05: Timeline of cholesterol lowering drugs Exhibit 06: Market dynamics for hypercholesterolemia Exhibit 07: Prescription landscape for statins 2015 Exhibit 08: Prescription landscape for ezetimibe 2015 Exhibit 09: Prescription landscape for other classes 2015 Exhibit 10: Distribution of cholesterol-lowering medication for individuals above 40 years Exhibit 11: Percentage use of prescription cholesterol-lowering medication in US for various indications 2015 Exhibit 12: Treatment of hypercholesterolemia Exhibit 13: Pharmacological treatment of hypercholesterolemia Exhibit 14: High cholesterol levels by race and ethnicity in US 2015 Exhibit 15: PCSK9 inhibitors in preclinical and clinical development 2015 Exhibit 16: Pipeline portfolio: Global hypercholesterolemia drugs market Exhibit 17: Pipeline share of hypercholesterolemia drugs Exhibit 18: Global hypercholesterolemia drugs market 2015-2020 ($ billions) Exhibit 19: Five forces analysis Exhibit 20: Classification of hyperlipidemia Exhibit 21: Global hypercholesterolemia market segmentation by MOA Exhibit 22: Global hypercholesterolemia market segmentation by MoA 2015 Exhibit 23: Global hypercholesterolemia drugs market segmentation by drug class Exhibit 24: Global hypercholesterolemia drugs market by drug class 2015 (% share) Exhibit 25: Hypercholesterolemia drugs market revenue by drug class 2015-2020 ($ billions) Exhibit 26: Global statin market 2015-2020 ($ billions) Exhibit 27: Number of prescriptions for statins in US Exhibit 28: Usage of statins for hypercholesterolemia in US 2015 Exhibit 29: Usage of statins for hypercholesterolemia in UK 2015 Exhibit 30: Global non-statins market 2015-2020 ($ billions) Exhibit 31: Number of prescriptions for non-statins in US Exhibit 32: Global hypercholesterolemia drugs market: YoY growth and revenue based on drug class 2015-2020 Exhibit 33: Segmentation of global hypercholesterolemia drugs markets by geography 2015 Exhibit 34: Hypercholesterolemia drugs market revenue by geography 2015-2020 ($ billions) Exhibit 35: Percentage share of hypercholesterolemia drugs market by geography 2015-2020 (%) Exhibit 36: Hypercholesterolemia drugs market in Americas 2015-2020 ($ billions) Exhibit 37: Share of hypercholesterolemia drugs market in Americas by country 2015 Exhibit 38: Hypercholesterolemia drugs market in EMEA 2015-2020 ($ billions) Exhibit 39: Hypercholesterolemia drugs market in APAC 2015-2020 ($ billions) Exhibit 40: Global hypercholesterolemia drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 41: Population aged 60 years and over: World, developed and developing regions ($ millions) Exhibit 42: Impact of drivers Exhibit 43: Impact of drivers and challenges Exhibit 44: Arguments for and against OTC switch by pharmaceutical companies and regulatory organizations Exhibit 45: Market share analysis of global hypercholesterolemia drugs market 2015 Exhibit 46: Revenue from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions) Exhibit 47: AbbVie: YoY revenue and growth rate of lipid franchise portfolio 2013-2015 ($ millions) Exhibit 48: Key takeaways Exhibit 49: Aegerion: YoY revenue and growth rate of JUXTAPID 2013-2015 ($ millions) Exhibit 50: Key takeaways Exhibit 51: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions) Exhibit 52: AstraZeneca: Geographic segmentation of Crestor 2015 by revenue Exhibit 53: Key takeaways Exhibit 54: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions) Exhibit 55: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions) Exhibit 56: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions) Exhibit 57: Merck: Key takeaways Exhibit 58: Pfizer: YoY revenue and growth rate of Lipitor 2013-2015 ($ billions) Exhibit 59: Pfizer: Geographic segmentation of Lipitor by revenue 2015 Exhibit 60: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions) Exhibit 61: Key takeaways Exhibit 62: Sanofi: Key takeaways

AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, Zydus Cadila.